Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals

被引：0
|
作者：
Andreas Schick
Kathleen L. Miller
Michael Lanthier
Gerald Dal Pan
Clark Nardinelli
机构：
[1] U.S. Food and Drug Administration,Office of Program and Strategic Analysis, Center for Drug Evaluation and Research
[2] U.S. Food and Drug Administration,Office of Planning, Office of the Commissioner
[3] U.S. Food and Drug Administration,Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research
来源：
Drug Safety | 2017年 / 40卷
关键词：
Boxed Warning; Safety Action; Priority Review; Goal Date; Restricted Indication;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：497 / 503
页数：6
相关论文
共 50 条
  • [31] Post-marketing drug safety in the era of genomic medicine
    Zavras, AI
    JOURNAL OF DENTAL RESEARCH, 2005, 84 (02) : 105 - 106
  • [32] Utilization of Genomic Biomarkers for Post-marketing Safety of Drugs
    Kaniwa, Nahoko
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2015, 135 (05): : 671 - 679
  • [33] Post-Marketing Safety Surveillance: Incorporation of a Test for Trends
    Kellier-Steele, Nicole
    Thompson, E. Alan
    Crowe, Brenda
    Hornbuckle, Kenneth
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 109 - 110
  • [34] Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone
    Mendes, Diogo
    Alves, Carlos
    Batel-Marques, Francisco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (12) : 1259 - 1270
  • [35] Fluvoxamine: Safety profile in extensive post-marketing surveillance
    Buchberger, R
    Wagner, W
    PHARMACOPSYCHIATRY, 2002, 35 (03) : 101 - 108
  • [36] The safety of risperidone: a post-marketing study on 7684 patients
    Mackay, FJ
    Wilton, LV
    Pearce, GL
    Freemantle, SN
    Mann, RD
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1998, 13 (06) : 413 - 418
  • [37] Post-marketing safety profile of ezetimibe in black patients
    Lehman, Heidi
    Andrulonis, David
    Adamsons, Ingrid
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S134 - S134
  • [38] Enhancing the Presentation and Evaluation of Cumulative Post-Marketing Safety Data; a Pilot Study
    Gilchrist, Anna
    Layton, Deborah
    Fogg, Carole
    Shakir, Saad
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S338 - S339
  • [39] Post-marketing safety experience of vedolizumab in patients with pre-existing viral hepatitis
    Wu, Deng-Chyang
    Hilmi, Ida Normiha
    Adsul, Shashi
    Blake, Aimee
    Bhayat, Fatima
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 126 - 126
  • [40] Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
    Li, Zhao
    Guo, Changying
    Liu, Xingfei
    Qiu, Zhengzhou
    Zhang, Ruilin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345